Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

5 results
Display

Freedom to choose a cure: how safe is a deadly cancer?

Monsurro V

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions

Raus S, Coin S, Monsurro V

Multiple myeloma is a malignancy of B-cells that is characterized by the clonal expansion and accumulation of malignant plasma cells in the bone marrow. This disease remains incurable, and a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Next generation sequencing: new tools in immunology and hematology

Mori A, Deola S, Xumerle L, Mijatovic , Malerba G, Monsurro V

One of the hallmarks of the adaptive immune system is the specificity of B and T cell receptors. Thanks to somatic recombination, a large repertoire of receptors can be generated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Mechanism of Immune Response During Immunotherapy

Panelli MC, Nagorsen D, Wang E, Monsurro V, Jin P, Katia Z, Smith K, Ngalame Y, Marincola

Tumor immunology embraces an extensive array of biological phenomena that include interactions between neoplastic cells and the innate and adaptive immune response. Among immune cells, T cells have taken the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune Monitoring of Cancer Vaccines

Wang E, Panelli MC, Monsurro V, Ping J, Zavaglia K, Marincola

The recent progress in tumor immunology exemplifies the successful application of modern biotechnology for the understanding of the complex natural or therapy-induced phenomenon of immune-mediated rejection of cancer. Tumor antigens...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr